As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications. On May 18, 2021, Québec announced that, subject to exceptions, patients who use a reference biologic for which one or more biosimilars are available will have to switch, under the supervision of their doctor, to a biosimilar drug by April 12, 2022. According to the announcement, this shift will result in annual savings of over $100 million dollars. Québec’s website on biosimilar drugs includes a section on the current situation regarding reimbursement.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – March 2023
In this article, we provide a further update on developments regarding biosimilars in Canada.Read More -
CADTH consultation on time-limited reimbursement initiative, and IMC report on what Canada can learn from Europe
The Canadian Agency for Drugs and Technologies in Health has released a consultation document for a Proposed Process for Time-limited Reimbursement Recommendations.Read More -
House of Commons Standing Committee on Health meets for study of the PMPRB
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).Read More